M&T Bank Corp Has $139.98 Million Stock Position in Danaher Co. (NYSE:DHR)

M&T Bank Corp reduced its stake in shares of Danaher Co. (NYSE:DHR) by 0.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 503,497 shares of the conglomerate’s stock after selling 946 shares during the quarter. M&T Bank Corp owned 0.07% of Danaher worth $139,982,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Benjamin Edwards Inc. boosted its stake in Danaher by 1.8% in the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock valued at $538,000 after buying an additional 38 shares in the last quarter. Wedge Capital Management L L P NC boosted its stake in Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after buying an additional 38 shares in the last quarter. Patrick M Sweeney & Associates Inc. raised its position in Danaher by 3.4% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock valued at $307,000 after purchasing an additional 40 shares during the last quarter. Trust Co of Kansas raised its position in Danaher by 4.1% in the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after purchasing an additional 40 shares during the last quarter. Finally, Abacus Planning Group Inc. raised its position in Danaher by 0.7% in the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after purchasing an additional 40 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price for the company in a research report on Thursday, October 31st. Evercore ISI increased their target price on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. KeyCorp increased their target price on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. TD Cowen increased their target price on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Finally, Barclays lowered their price objective on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average target price of $287.16.

Danaher Stock Performance

Shares of DHR opened at $235.91 on Tuesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The stock has a 50-day moving average of $249.91 and a 200-day moving average of $258.14. The company has a market cap of $170.39 billion, a PE ratio of 45.02, a P/E/G ratio of 4.23 and a beta of 0.83. Danaher Co. has a one year low of $217.96 and a one year high of $281.70.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same period last year, the business posted $2.02 EPS. On average, equities research analysts predict that Danaher Co. will post 7.5 EPS for the current fiscal year.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.